Compare Smith & Nephew plc (SNN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Smith & Nephew plc trades at $27.67 (market cap $11.63B), while Vanguard Short Term Corporate Bond ETF trades at $78.09. The key difference: Smith & Nephew plc pays a 2.85% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals.
| SNN | VCSH | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Fixed Income |
52-Week High | $38.53 | $80.20 |
52-Week Low | $27.80 | $78.08 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $78.14 with minimal daily movement (-0.05%). The technical picture is bearish with moving averages signaling caution, though oversold RSI readings suggest potential near-term support. The ETF maintains a competitive 4.5% dividend yield with a short 2.7-year duration, positioning it defensively against rising rates while offering higher income than treasury alternatives.
While VCSH provides quality short-term corporate bond exposure with minimal interest rate risk, current tight credit spreads limit upside potential. The ETF faces competition from broader bond funds and carries corporate credit risk. Recent analyst downgrades to 'Hold' reflect concerns about entry timing, though institutional investors continue active positioning in the fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
